Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;33(6):28-34.

Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations

Derrick Robertson  1 , Natalie Moreo  1
Affiliations

Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations

Derrick Robertson et al. Fed Pract. 2016 Jun.

Abstract

Controlling symptoms can slow the physical and emotional disabilities associated with multiple sclerosis and help patients attain the highest quality of life possible for as long as possible.

PubMed Disclaimer

References

    1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–911. - PubMed
    1. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(pt 5):1175–1189. - PMC - PubMed
    1. Charil A, Filippi M. Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J Neurol Sci. 2007;259(1–2):7–15. - PubMed
    1. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol. 2009;65(3):239–248. - PubMed
    1. Grigoriadis N, van Pesch V ParadigMS Group. A basic overview of multiple sclerosis immunopathology. Eur J Neurol. 2015;22(suppl 2):3–13. - PubMed

LinkOut - more resources